274 related articles for article (PubMed ID: 16845534)
1. Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
Gillatt D
J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S17-26. PubMed ID: 16845534
[TBL] [Abstract][Full Text] [Related]
2. What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?
Mason M
J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S27-35. PubMed ID: 16896883
[TBL] [Abstract][Full Text] [Related]
3. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
[TBL] [Abstract][Full Text] [Related]
4. The role of antiandrogen monotherapy in the treatment of prostate cancer.
Anderson J
BJU Int; 2003 Mar; 91(5):455-61. PubMed ID: 12603397
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
Mahler C; Verhelst J; Denis L
Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
[TBL] [Abstract][Full Text] [Related]
6. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
[TBL] [Abstract][Full Text] [Related]
7. Safety of antiandrogen therapy for treating prostate cancer.
Ricci F; Buzzatti G; Rubagotti A; Boccardo F
Expert Opin Drug Saf; 2014 Nov; 13(11):1483-99. PubMed ID: 25270521
[TBL] [Abstract][Full Text] [Related]
8. Nilutamide: an antiandrogen for the treatment of prostate cancer.
Dole EJ; Holdsworth MT
Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
[TBL] [Abstract][Full Text] [Related]
9. Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
BJU Int; 2015 Jul; 116(1):30-6. PubMed ID: 25523493
[TBL] [Abstract][Full Text] [Related]
10. Treatment of locally advanced prostate cancer--a new role for antiandrogen monotherapy?
Abrahamsson PA
Eur Urol; 2001; 39 Suppl 1():22-8. PubMed ID: 11114597
[TBL] [Abstract][Full Text] [Related]
11. Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?
Boccon-Gibod L
Eur Urol; 1998; 33(2):159-64. PubMed ID: 9519357
[TBL] [Abstract][Full Text] [Related]
12. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
Sciarra A; Cardi A; Di Silverio F
Urol Int; 2004; 72(2):91-8. PubMed ID: 14963347
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer.
McLeod DG
Oncologist; 1997; 2(1):18-27. PubMed ID: 10388026
[TBL] [Abstract][Full Text] [Related]
14. Antiandrogens in the treatment of prostate cancer.
Wirth MP; Hakenberg OW; Froehner M
Eur Urol; 2007 Feb; 51(2):306-13; discussion 314. PubMed ID: 17007995
[TBL] [Abstract][Full Text] [Related]
15. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
Tyrrell CJ; Kaisary AV; Iversen P; Anderson JB; Baert L; Tammela T; Chamberlain M; Webster A; Blackledge G
Eur Urol; 1998; 33(5):447-56. PubMed ID: 9643663
[TBL] [Abstract][Full Text] [Related]
16. Antiandrogens as monotherapy for prostate cancer.
Schröder FH
Eur Urol; 1998; 34 Suppl 3():12-7. PubMed ID: 9854190
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.
Kolvenbag GJ; Iversen P; Newling DW
Urology; 2001 Aug; 58(2 Suppl 1):16-23. PubMed ID: 11502439
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
19. Antiandrogen monotherapy: indications and results.
Iversen P
Urology; 2002 Sep; 60(3 Suppl 1):64-71. PubMed ID: 12231053
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogen monotherapy in the management of advanced prostate cancer.
Kaisary AV
Eur Urol; 1997; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]